Breast cancer is the most frequently diagnosed cancer in women, with estrogen receptor
positive (ER+) breast cancer making up approximately 75% of all breast cancers diagnosed …

Endocrine therapy is a crucial treatment for estrogen receptor-positive (ER+) breast cancer,
with proven clinical benefits. However, adaptive mechanisms emerge in the tumor, causing …

Advanced Breast Cancer (ABC) comprises both locally advanced breast cancer (LABC) and
metastatic breast cancer (MBC)[1]. Although treatable, MBC remains virtually an incurable …

Background Activation of the PI3K/AKT/mTOR pathway occurs frequently in breast cancer
that is resistant to endocrine therapy. Approved mTOR inhibitors effectively inhibit cell …

Purpose The mammalian target of rapamycin inhibitor everolimus targets aberrant signaling
through the PI3K/AKT/mammalian target of rapamycin pathway, a mechanism of resistance …

Endocrine therapy, a major modality in the treatment of hormone receptor (HR)–positive
breast cancer (BCA), has improved outcomes in metastatic and nonmetastatic disease …

Importance Everolimus plus exemestane and capecitabine are approved second-line
therapies for advanced breast cancer. Objective A postapproval commitment to health …

Male breast cancer is rare, accounting for 1% of all breast cancer diagnoses in the USA.
Because of its rarity, most major breast cancer trials have included only female patients. This …

Background The phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin
(mTOR) pathway (PI3K/AKT/mTOR pathway) plays a key role in cancer. We performed this …

Metastatic breast cancer (MBC) is the leading cause of cancer-related morbidity and
mortality among women worldwide. Endocrine therapy is the standard of care for the most …